This is an international site for FEMARA^® (letrozole) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Welcome to the Femara Product Website

FEMARA is approved for use in 104 countries around the world.

FEMARA Country-Level Websites

Below is a list of the countries that host a FEMARA website based on local label and in local language. They are intended for Health Care Professionals (HCPs) only. If you are a HCP from one of the countries listed below, click on your country link to be redirected to your country Femara website.

FEMARA International Website

This website is intended for Health Care Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)

FEMARA^® patient case study #2: Emma

Clinical profile

Age 55
Stage IIB
Postmenopausal
Comorbidity: Osteoporosis

Breast cancer characteristics

ER+/PR+
T3 (1.5 cm)
Grade 1
2 positive nodes
HER-2/neu-
Modified radical mastectomy
Radiation

What do you think about Emma's case?

Please click on the most appropriate response.

Disclaimer: This is an international website for Femara^® (letrozole) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.